Why the study?
Does combination therapy with ACE inhibitors and calcium antagonists reduce hypertensive target organ disease in patients with hypertension compared to monotherapy?
Does combination therapy with ACE inhibitors and calcium antagonists reduce hypertensive target organ disease in patients with hypertension compared to monotherapy?
Answers are grounded in this paper and cite their sources.
Combination therapy with ACE inhibitors and calcium antagonists shows theoretical promise for hypertensive target organ disease, but requires validation through prospective randomized trials.
Hypertension control and management of concomitant pathophysiologic conditions may require use of multiple drugs. However, most studies in hypertensive disease have focused on monotherapy. Therefore, our knowledge of combination therapy in the treatment of hypertension is largely extrapolated from these monotherapy studies. Angiotensin-converting enzyme (ACE) inhibitors and calcium antagonist combinations should be particularly efficacious in reducing hypertensive target organ disease. Both of these drug classes have been shown to reduce complications of hypertensive heart disease and renal disease progression. With regard to hypertensive vascular disease, both ACE inhibitors and calcium antagonists have documented benefits. However, their use together in left ventricular hypertrophy and in patients with coronary heart disease, although promising, must be proved through carefully designed, prospective, randomized trials.
No takes yet. Share an insight, caveat, or question.
Franz H. Messerli (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: